Further studies are necessary to identify signaling pathway(s) and cell type(s) mediating the anti-tumorigenic effects of PEDF in pancreatic cancer, highlighting the impact of PEDF on both parenchymal and mesenchymal cell compartments during pancreatic cancer progression. This evidence concerns the gene SERPINF1 and familial pancreatic carcinoma.